With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...
If the enhanced credits currently available to Affordable Care Act (ACA) Marketplace enrollees are allowed to expire for 2026 ...
The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
The influencer has been sharing her postpartum health journey, adding GLP-1 medication to her Weight Watchers program.
11h
My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
Even when Americans have health insurance, they can have a hard time affording the drugs they've been prescribed.
US health technology assessor the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report ...
Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback